// App-Quantinova.ai

: Durability of mepolizumab treatment response between doses

Researchers

Presenter

  • Ian Douglas Pavord

Principal Investigators

  • Peter Howarth

  • Daniel J Bratton

  • Frank C Albers

  • Steven Yancey

Medical Centers

  • Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford and NIHR Oxford Respiratory Biomedical Research Centre, Oxford, United Kingdom

  • Global Medical Franchise, GSK House, Brentford, United Kingdom,

  • Clinical Statistics, GSK, Stockley Park, Uxbridge, Middlesex, United Kingdom,

  • Respiratory Medical Franchise, GSK, Research Triangle Park, NC, United States,

  • Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, United States.

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Recepteur d'Origine Nantais

Drug/Treatment

  • Mepolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved